NG Bio LTD (“NG Bio”) today announces the appointment of Martin Bloom to the NG Bio Board of Directors.

“Martin’s exceptional background in scaling biotech companies and securing public listings on major global exchanges, paired with his strategic insights in biotech, makes him a tremendous asset for NG Bio as we drive forward our mission to extend healthy life spans,” said Mohammad Khobreh, Managing Partner at NG Bio. “His experience and vision will greatly enhance our efforts to create transformative medicines and diagnostics that address the root causes of chronic diseases.”

Martin has had a portfolio career spanning three continents. He has invested actively over almost 30 years in numerous technology and biotech companies, sitting on several boards, and investing in several venture capital and private equity funds (sitting on the Corporate Advisory Board of one). Martin went on to lead a number of high tech companies, including six listings on the NYSE, LSE Main Market and the AIM as Board Chair or Director.

Martin Bloom sees “NG Bio at an exciting point in the development of human medicine, the confluence of immunology with the increasing realisation that inflammation underpins many of the major diseases affecting humans. This is an excellent time for NG Bio to create financial value.”

About NG Bio
NG Bio, an early-stage investor and venture builder addressing the harmful immune responses, such as inflammation, that cause or exacerbate many of the major human diseases. By tackling these, we extend human health span and longevity.